Correlation Between Monopar Therapeutics and Maravai Lifesciences

Can any of the company-specific risk be diversified away by investing in both Monopar Therapeutics and Maravai Lifesciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Monopar Therapeutics and Maravai Lifesciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Monopar Therapeutics and Maravai Lifesciences Holdings, you can compare the effects of market volatilities on Monopar Therapeutics and Maravai Lifesciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Monopar Therapeutics with a short position of Maravai Lifesciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Monopar Therapeutics and Maravai Lifesciences.

Diversification Opportunities for Monopar Therapeutics and Maravai Lifesciences

-0.82

Correlation Coefficient

Monopar Therapeutics  Maravai Lifesciences

Pay attention - limited upside

The 3 months correlation between Monopar and Maravai is -0.82. Overlapping area represents the amount of risk that can be diversified away by holding Monopar Therapeutics and Maravai Lifesciences Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Maravai Lifesciences and Monopar Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Monopar Therapeutics are associated (or correlated) with Maravai Lifesciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Maravai Lifesciences has no effect on the direction of Monopar Therapeutics i.e., Monopar Therapeutics and Maravai Lifesciences go up and down completely randomly.

Pair Corralation between Monopar Therapeutics and Maravai Lifesciences

Given the investment horizon of 90 days Monopar Therapeutics is expected to generate 12.03 times more return on investment than Maravai Lifesciences. However, Monopar Therapeutics is 12.03 times more volatile than Maravai Lifesciences Holdings. It trades about 0.13 of its potential returns per unit of risk. Maravai Lifesciences Holdings is currently generating about -0.06 per unit of risk. If you would invest  386.00  in Monopar Therapeutics on September 13, 2024 and sell it today you would earn a total of  2,042  from holding Monopar Therapeutics or generate 529.02% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Monopar Therapeutics  vs.  Maravai Lifesciences Holdings

Monopar Therapeutics

Risk-Adjusted Performance

10 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Monopar Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Even with relatively inconsistent basic indicators, Monopar Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Maravai Lifesciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Maravai Lifesciences Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite abnormal performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Pair Trading with Monopar Therapeutics and Maravai Lifesciences

The main advantage of trading using opposite Monopar Therapeutics and Maravai Lifesciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Monopar Therapeutics position performs unexpectedly, Maravai Lifesciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Maravai Lifesciences will offset losses from the drop in Maravai Lifesciences' long position.

The idea behind Monopar Therapeutics and Maravai Lifesciences Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.